9 小时
Pharmaceutical Technology on MSNFDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseasesApellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...
Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果